CHEMOCENTRYX INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of ChemoCentryx, Inc. - CCXI

NEW ORLEANS, Feb. 18, 2022

On May 4, 2021, the U.S. Food and Drug Administration (the "FDA") issued briefing documents regarding the  New Drug Application for the Company's drug candidate, avacopan, In the disclosure, the FDA noted that "[c]omplexities of the study design…raise questions about the interpretability of the data to define a clinically meaningful benefit of avacopan" and that the review had "identified several areas of concern, raising uncertainty about the interpretability of the data and the clinical meaningfulness of these results."

Thereafter, the Company and certain of its executives were sued in a securities class action lawsuit, charging them with failing to disclose material information in violation of federal securities laws, which remains ongoing. 

KSF's investigation is focusing on whether ChemoCentryx's officers and/or directors breached their fiduciary duties to the Company's shareholders or otherwise violated state or federal laws. 

If you have information that would assist KSF in its investigation, or have been a long-term holder of ChemoCentryx shares and would like to discuss your legal rights, you may, without obligation or cost to you, call toll-free at 1-877-515-1850 or email KSF Managing Partner Lewis Kahn (lewis.kahn@ksfcounsel.com), or visit https://www.ksfcounsel.com/cases/nasdaqgs-ccxi/ to learn more.

About Kahn Swick & Foti, LLC